Synthesis of fluvirucins and their aglycons, the fluvirucinins by Amat Tusón, Mercedes et al.
2705
M. Amat et al. Short ReviewSyn thesis
SYNTHESIS0 0 3 9 - 7 8 8 1 1 4 3 7 - 2 1 0 X
© Georg Thieme Verlag  Stuttgart · New York
2016, 48, 2705–2720
short review
ich
 g
es
ch
üt
zt
.Synthesis of Fluvirucins and Their Aglycons, the Fluvirucinins
Mercedes Amat* 
Núria Llor 
Guillaume Guignard 
Joan Bosch*
Laboratory of Organic Chemistry, Faculty of Pharmacy, and 
Institute of Biomedicine (IBUB), University of Barcelona, 
Av. Joan XXIII 27-31, 08028 Barcelona, Spain
amat@ub.edu
joanbosch@ub.edu
HN
O
RO
HN
O
OR
Fluvirucin B2 (Sch 38518)R = O
Me
OH
HO
H2N
Fluvirucin A1
Fluvirucinin A1     R = H
O
OH
OH
NH2
R =
Fluvirucinin B2        R = HH
er
un
te
rg
el
ad
en
 v
on
: U
ni
ve
rs
id
ad
 d
e 
Ba
rc
el
on
a.
 U
rh
eb
er
re
ch
tlReceived: 21.04.2016
Accepted after revision: 29.04.2016
Published online: 23.06.2016
DOI: 10.1055/s-0035-1561469; Art ID: ss-2016-z0272-sr
Abstract Fluvirucins are bioactive macrolactam glycosides isolated
from actinomycetes. This review gives an overview of this family of nat-
ural products, covering isolation, biological activities, biosynthesis, and
total synthesis. The synthesis of fluvirucins and their aglycons, the flu-
virucinins, is presented, paying special attention to the synthetic strate-
gy and stereochemical aspects.
1 Introduction
2 Isolation, Biological Activity, and Biosynthesis
3 Synthetic Approaches
3.1 Closure of the 14-Membered Ring by Ring-Closing Metathesis
3.2 Closure of the 14-Membered Ring by Macrolactamization
3.3 Construction of the 14-Membered Ring by Aza-Claisen Ring Ex-
pansion
4 Conclusion
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1 Introduction
Fluvirucins are a family of naturally occurring glyco-
sides structurally characterized by the presence of an ami-
no sugar attached at the C-3 or C-9 position of a 14-mem-
bered macrocycle lactam aglycon. They also incorporate a
methyl or ethyl substituent at C-2 [(S)-1-hydroxyethyl in
fluvirucin A2], C-6 (absent in some members), and C-10 of
the core lactam nucleus. The amino sugar moiety can be 3-
amino-3,6-dideoxy-α-L-talopyranose, e.g. in fluvirucins A1
and B1, or its 4-epimer (L-mycosamine), e.g. in fluvirucin B2,
or an N-substituted derivative of either.
2 Isolation, Biological Activity, and Biosyn-
thesis
The first member of the fluvirucin family (Sch 38516)
was reported in 1990 by scientists at Schering–Plough, who
obtained it by extraction from the fermentation broth of
the actinomycete Actinomadura vulgaris.1 Its structure was
established by X-ray crystallographic analysis. In the fol-
lowing years, the same group reported the isolation of sev-
en other glycosides (Sch 38511–38513, Sch 38518, and
their C-4′ epimers) produced by various species of Acti-
nomadura.2,3 (Figure 1). All these compounds were found to
exhibit antifungal activity against various strains of Candi-
da sp. and dermatophytes.
Almost simultaneously, scientists at Bristol–Myers
Squibb described seven macrolactam glycosides, named
fluvirucins A1, A2, and B1–B5, from several actinomycete
strains. These fluvirucins possess inhibitory activity against
the influenza A virus,4 which is partially retained in the
corresponding fluvirucinins.4b
Fluvirucin B2 also acts as an inhibitor of phosphatidyl-
inositol-specific phospholipase C.5 The structures of some
of these fluvirucins coincided with those previously report-
ed by the Schering–Plough researchers.
More recently, researchers at Merck have reported the
isolation of fluvirucin B06 and two new N-methyl deriva-
tives of fluvirucin A17 from the actinomycete Nonomuraea
turkmerniaca, all of which show anthelmintic activity.
By 13C feeding experiments, it was demonstrated that
the aglycon moiety of fluvirucins is biosynthesized from
acetate and propionate via a combination of polyketide and
tricarboxylic acid mechanisms.4b,8 In this context, the iden-
tification and characterization of the putative polyketide© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 2705–2720
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t.synthase genes associated with fluvirucin B1 aglycon bio-
synthesis in Actinomadura vulgaris has recently been re-
ported.9
3 Synthetic Approaches
The synthesis of fluvirucins has been little explored. In
fact, only one total enantioselective synthesis of a member
of this group, fluvirucin B1, has been reported to date. In
contrast, fluvirucinins have received considerable attention
from the synthetic standpoint, which has resulted in enan-
tioselective syntheses of fluvirucinins A1, A2, B0, B1, and B2–5,
the latter being the aglycon common to fluvirucins B2, B3,
B4, and B5.
Two key issues in the synthesis of fluvirucins and flu-
virucinins are the closure of a 14-membered lactam ring
and the control of the configuration of its stereocenters.
As outlined in Figure 2, three main strategies have been
used for the construction of the macrocyclic ring: 1. olefin
ring-closing metathesis reaction (bond formed C4–C5, C5–C6,
C6–C7, or C8–C9); 2. macrolactamization (bond formed N–
C1); and 3. amide–enolate-induced ring expansion via aza-
Claisen rearrangement of a 10-membered 1-acyl-2-
alkoxyvinyl-azacycle (bond formed C2–C3).
For the sake of clarity, the carbon numbering used in
this review for the synthetic intermediates corresponds to
that of the fluvirucinin system. In addition, to facilitate its
visualization, the fluvirucinin ring skeleton has been drawn
with the same orientation throughout the review, both in
the A and B series.
3.1 Closure of the 14-Membered Ring by Ring-
Closing Metathesis
3.1.1 Hoveyda’s Approach to Fluvirucinin B1 and Flu-
virucin B1
The first synthesis of a fluvirucinin was reported by
Hoveyda in 1995.10 Two relevant aspects of the synthesis
are the use of a ring-closing metathesis (RCM) reaction to
promote stereoselective macrocyclization from a conforma-
tionally mobile acyclic diene, and the use of macrocyclic
stereocontrol to establish the remote stereochemistry at C-6
by catalytic hydrogenation. Thus, closure of the 14-mem-
bered ring was efficiently accomplished (bond formed C5–
C6) under smooth conditions, using the Schrock Mo cata-
lyst, from amido diene 3, which was convergently prepared
by coupling of acid 1 with amine 2 (Scheme 1). Catalytic hy-
drogenation of the resulting trisubstituted Z olefin 4 stereo-
selectively installed the C-6 stereogenic center to afford, af-
ter deprotection, fluvirucinin B1, which was converted into
the corresponding acetate.10,11
The required starting materials 1 and 2 (C1–C5 and C6–N
fragments, respectively, of fluvirucinin B1), which incorpo-
rate the C-2, C-9, and C-10 stereogenic centers of fluviruci-
nin B1, were prepared as outlined in Scheme 2.10,11 Acid 1,
with the required R configuration, was prepared from dihy-
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t.drofuran 5 via a sequence of three metal-catalyzed steps.
Enantioselective Zr-catalyzed ethylmagnesation of 5 gave
homoallylic alcohol 6, which was subjected to a tandem Ti-
and Ni-catalyzed hydrovinylation by hydromagnesation of
the olefin, followed by in situ cross-coupling reaction of the
resulting Grignard reagent 7 with vinyl bromide. Ru-cata-
lyzed oxidation of the resulting alcohol 8 completed the
synthesis of acid 1.
In turn, homoallylic alcohol 9 was converted into enan-
tiopure allylic alcohol 10 (>99% ee) via kinetic Sharpless
resolution of the corresponding racemate. Subsequent one-
pot double alkylation of the monosubstituted olefin moiety
of 10, involving a diastereoselective Zr-catalyzed ethylmag-
nesation, and in situ trapping of the resulting alkylmagne-
sium halide intermediate 11 with N-tosylaziridine, afforded
12 (dr = 97:3). Final protection–deprotection steps led to
amine 2 in 12% overall yield for the six-step procedure.
The same strategy was employed for the synthesis of
fluvirucin B1 (Sch 38516), which incorporates a novel car-
bohydrate moiety identified for the first time in a natural
product. However, all attempts to glycosylate the deprotect-
ed alcohol derived from 4 with a variety of carbohydrate
derivatives failed, probably due to the low solubility of the
macrocyclic alcohol in organic solvents.
This problem was circumvented using the more readily
soluble alcohol resulting from deprotection of acyclic diene
3, which underwent stereoselective glycosylation with
fluoroglycoside 13 to give 14 in excellent yield (Scheme 3).
Subsequent RCM, followed by stereoselective hydrogena-
tion of the resulting Z-unsaturated macrolactam 15 and
deprotection of the sugar moiety, afforded fluvirucin B1
(Sch 38516).11,12 This was the first, and to date the only,
synthesis of a member of the fluvirucin family.
Scheme 1  Final steps of Hoveyda’s synthesis of fluvirucinin B1
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Figure 2  Closure of the 14-membered lactam ring
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Figure 1  Structures of fluvirucins
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t.The carbohydrate fragment 20 of fluvirucin B1 was pre-
pared from ethyl sorbate (16) as illustrated in Scheme 4.
Key steps of the synthesis are catalytic Sharpless asymmet-
ric (80% ee) dihydroxylation of 16, which ensured the opti-
cal purity, diastereoselective dipolar [3+2] cycloaddition
between (R)-α-methylbenzylamine-derived nitrone 18 and
vinylene carbonate, and the removal of the protecting
groups from the resulting cycloaddition product 19 by con-
trolled acid hydrolysis and hydrogenolysis. The stereo-
chemical identity of 20 was established through conversion
into the corresponding O,O,N-triacetyl methyl glycoside,
which proved identical to the material obtained from deg-
radation of natural fluvirucin B1.
To perform the crucial glycosylation reaction, 20 was
protected as an O,O-diacetyl-N-trifluoroacetyl derivative
and then activated as a fluoroglycoside 13 via acetoxyglyco-
side 21 and a thioglycoside.11–13
3.1.2 Bracher’s Approach to Fluvirucinin B0
In 2002, Bracher reported14 the enantioselective synthe-
sis of 6-norfluvirucinin B1 before it was known that this nor
derivative was the aglycon of fluvirucin B0. The closure of
the macrolactam ring was also achieved by RCM reaction,
Scheme 2  Preparation of C1–C5 and C6–N fragments in Hoveyda’s synthesis of fluvirucinin B1
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t.although, in this case, involving the formation of the C4–C5
bond.
The required amido diene 24, which incorporates the
three stereocenters of fluvirucinin B0, was synthesized by
coupling acid 22 with amine 23 (C1–C4 and C5–N fragments
of fluvirucinin B0). The RCM of 24 was satisfactorily per-
formed with Grubbs’ catalyst, in the presence of Ti(Oi-Pr)4
to avoid the formation of an unproductive Ru chelate with
the γ,δ-unsaturated amide. Subsequent catalytic hydroge-
nation of the resulting diene 25 led to fluvirucinin B0
(Scheme 5).
Scheme 6  Preparation of (R)-2-ethylpent-4-enoic acid
Enantiopure acid 22 was prepared in two steps from
Oppolzer’s N-crotyl-(+)-camphorsultam 26,15 by conjugate
hydride addition followed by trapping of the resulting eno-
late with allyl bromide and subsequent hydrolysis of N-
acylsultam 27 (Scheme 6).
In turn, amine 23 was obtained from epoxy alcohol 28,
which was accessible by Sharpless oxidation of the corre-
sponding (E)-pentenol.16 After protection of the hydroxy
group, regio- and stereoselective ring-opening reaction
with an alkynyl alanate derived from 29 gave alcohol 30,
which was converted into saturated epoxide 31. Regioselec-
tive opening of 31 with 3-butenylmagnesium bromide, fol-
lowed by protection–deprotection steps and conversion of
the primary alcohol function of 32 into a primary amino
group, completed the synthesis of the amine half 23
(Scheme 7).14
3.1.3 Radha Krishna’s Approach to Fluvirucinin A1
In 2011, Radha Krishna reported17 an enantioselective
synthesis of fluvirucinin A1 involving the same C4–C5 bond
disconnection. Closure of the macrocyclic ring was also
achieved by RCM reaction, in this case from diene 35, which
was prepared in nearly quantitative yield by amidation be-
tween carboxylic acid 33 and amine 34 (C1–C4 and C5–N
fragments of fluvirucinin A1). Hydrogenation of the result-
ing unsaturated macrolactam 36 (Z/E mixture) brought
about both the reduction of the olefinic bond and the
deprotection of the alcohol function to furnish fluvirucinin
A1 (Scheme 8).
Both fragments, 33 and 34, were accessed from a com-
mon intermediate 38 derived from (S)-Roche ester 37,
which provided the C-2 and C-6 stereogenic centers of flu-
virucinin A1. Conversion of ester 37 into allylic alcohol 3818
followed by Sharpless asymmetric epoxidation afforded ep-
oxy alcohol 39,18b which was converted into allylic alcohol
40 by Zn reduction of the corresponding iodide. Subsequent
protecting group interconversions and oxidation of the pri-
mary alcohol function afforded O-protected hydroxy acid
33 (Scheme 9).
Scheme 5  Final steps of Bracher’s synthesis of fluvirucinin B0
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Scheme 7  Preparation of the C5–N fragment in Bracher’s synthesis of fluvirucinin B0
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t.The preparation of amino-alkene 34 started with a
highly diastereoselective (dr > 95:5) Evans asymmetric
alkylation of N-butyryloxazolidinone 41 with the allylic
iodide derived from 38, which installed the C-10 stereogenic
center of fluvirucinin A1 (bond formed C9–C10). Reductive
cleavage of the chiral auxiliary, followed by a two-carbon
homologation of the resulting alcohol 43 gave alcohol 44,
which was converted into N-Boc-amino alcohol 45. Finally,
Swern oxidation and one-carbon Wittig olefination com-
pleted the C5–N fragment 34.
3.1.4 Negishi’s Approach to Fluvirucinin A1
An alternative enantioselective synthesis of fluvirucinin
A1, also using an RCM reaction to promote the macrocy-
clization, was reported in 2008 by Negishi,19 although, un-
like other syntheses, in this approach the bond formed was
C8–C9.
The required diene 48 was prepared in excellent yield
by amidation of acid 46 with amine 47 (C1–C8 and C9–N
fragments of fluvirucinin A1), and the RCM was performed,
also in excellent yield, using Grubbs I catalyst. Subsequent
hydrogenation of the olefinic double bond and deprotec-
tion afforded fluvirucinin A1 (Scheme 10).
Scheme 8  Final steps of Radha Krishna’s synthesis of fluvirucinin A1
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Scheme 9  Preparation of the C1–C4and C5–N fragments in Radha Krishna’s synthesis of fluvirucinin A1
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t.O-Protected hydroxy acid 46 was synthesized in nine
steps from (–)-(S)-β-citronellol (50), which provided the C-6
stereogenic center of the target macrocycle. The two other
stereocenters of 46 were stereoselectively (dr ≥ 98%) gener-
ated by Brown crotylboration20 of aldehyde 51, which led to
homoallylic alcohol 52 (Scheme 11). The synthesis of the
C1–C8 fragment was completed by oxidative cleavage of the
alkene moiety of 52, protection–deprotection steps, and
one-carbon Wittig olefination of the aldehyde resulting
from oxidation of alcohol 53.
Scheme 12  Preparation of the C9–N fragment in Negishi’s synthesis of 
fluvirucinin A1
Amino alkene 47 was obtained by two alternative
routes, both of them involving a Zr-catalyzed asymmetric
carboalumination reaction, followed by purification by
lipase-catalyzed acetylation, starting from either 3-buten-
1-ol (54a) or 4-penten-1-ol (54b). The resulting enantio-
merically pure (≥98% ee) (R)-2-ethyl-1-alkanols 56a and
56b, containing the C-10 asymmetric center of fluvirucinin
A, were converted into the C9–N fragment 47 in six conven-
tional steps, via alkenols 57a and 57b, as shown in Scheme
12.
3.1.5 The Vilarrasa–Urpí Approach to Fluvirucinin B2–5
In 2009, Vilarrasa and Urpí reported the first, and to
date the only, enantioselective synthesis of fluvirucinin B2–5,
the aglycon common to fluvirucins B2–B5, via an RCM reac-
tion involving the formation of the C6–C7 bond.21 The
macrocyclization was performed in the presence of the
Hoveyda–Grubbs (H–G) II catalyst using diene 60 as the
substrate, which was prepared by direct coupling of carbox-
ylic acid 58 with azide 59 using the Staudinger–Vilarrasa
reaction (Scheme 13).
Scheme 13  Final steps of the Vilarrasa–Urpí synthesis of fluvirucinin 
B2–5
Hydrogenation of the trisubstituted double bond of the
resulting unsaturated lactam 61 (1:1.2 mixture of Z/E iso-
mers) stereoselectively installed the C-6 stereogenic center
(9:1 dr); subsequent hydrolysis afforded fluvirucinin B2–5.
The corresponding acetate was found to be identical to the
reported acetylated aglycon derived from fluvirucin B2 (Sch
38518).
Both the ethyl-branched acid 58 and azide 59 (the C1–C6
and C7–N fragments of fluvirucinin B2–5) were stereoselec-
tively prepared from the same starting material, the
known22 allylated N-acyloxazolidinone 62 (Scheme 14),
which provided the C-2 and C-10 ethyl-substituted stereo-
genic centers of fluvirucinin B2–5.
Cross-metathesis of 62 with ethyl vinyl ketone, followed
by hydrogenation of the resulting carbon–carbon double
bond of enone 63 and selective Petasis ketone methylena-
Scheme 11  Preparation of the C1–C8 fragment in Negishi’s synthesis 
of fluvirucinin A1
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t.tion using DMF as a scavenger, afforded 64. Finally, hydro-
lytic removal of the chiral auxiliary provided acid 58 in ex-
cellent overall yield.
The conversion of 62 into azide 59 commenced with a
one-pot hydroboration–iodination process, followed by re-
placement of the iodine atom by an azide anion. After re-
ductive removal of the auxiliary in 65 and oxidation of the
resulting alcohol, stereoselective (dr ≥ 98:2) allylation of al-
dehyde 66 using the (S,S)-Leighton reagent installed the C-9
stereogenic center to give syn alcohol 67, which was pro-
tected as its TBS ether.
3.1.6 The Amat–Bosch Approach to Fluvirucinin B1
Our group has recently disclosed23 the enantioselective
synthesis of fluvirucinin B1, also employing an RCM reac-
tion to form the strategic C6–C7 bond in the key macrocy-
clization step.
This was accomplished from amido diene 70 (Scheme
15), which was prepared by coupling acid 68with amine 69
(the C1–C6 and C7–N fragments of fluvirucinin B1). The C-6
stereocenter was generated, as in previous syntheses, by
stereoselective hydrogenation of the trisubstituted double
bond of the macrocyclic alkene 71 (1.2:1 E/Z ratio), leading
to the O-protected fluvirucinin B1 derivative 72 (absolute
configuration unambiguously confirmed by X-ray crystallo-
graphic analysis). Finally deprotection gave fluvirucinin B1.
A distinctive feature of the synthesis is the use of (S)-
phenylglycinol-derived amino diol 75 as the common start-
ing material for the preparation of acid 68 and amine 69.
This amino diol provides the C-2 and C-10 ethyl substitu-
ents of the target aglycon, with the required absolute ste-
reochemistry. It was obtained from oxazolopiperidone lact-
am 73 by stereoselective alkylation followed by LiNH2·BH3
reduction of the resulting ethyl-substituted lactam 74, in a
process involving the simultaneous reductive opening of
the oxazolidine and lactam rings24 (Scheme 16).
Scheme 16  Preparation of the starting amino diol 75
Scheme 14  Preparation of the C1–C6 and C7–N fragments in the Vilarrasa–Urpí synthesis of fluvirucinin B2–5
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Scheme 15  Final steps of the Amat–Bosch synthesis of fluvirucinin B1
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75 was converted into the O-protected hydroxy acid 76 by
an unprecedented m-CPBA-promoted transformation in-
volving the regioselective oxidation of a phenylglycinol-
derived secondary amine to a carboxylic acid. Alternatively,
75 was converted into nitrile 78 by I2/NH3-mediated oxida-
tive cleavage of the secondary amino group (Scheme 17).
The synthesis of the C1–C6 fragment 68 from 76 was
completed, via iodide 77, by copper-catalyzed cross-cou-
pling reaction with 2-propenylmagnesium bromide, fol-
lowed by conversion of the alcohol function into a carboxy
group. In turn, the C7–N fragment 69 was synthesized from
nitrile 78, via aldehyde 79, by a diastereoselective Leighton
allylation (dr = 9:1), which introduced the stereogenic cen-
ter at C-9, and subsequent protection and reduction steps
from the resulting alcohol 80.
3.2 Closure of the 14-Membered Ring by Macrolac-
tamization
3.2.1 Trost’s Approach to Fluvirucinin B1
In 1997, Trost reported25 a synthesis of fluvirucinin B1
using a conceptually different approach, in which the mac-
rocyclic ring was assembled by lactamization.
Starting from N-acylimidazolidinone 87, two key inter-
mediates, Meldrum’s acid derivative 81 and epoxide 82 (C1–C5
and C6–N fragments of fluvirucinin B1), were synthesized in
enantiopure form. Coupling of these two building blocks
(bond formed C5–C6) by palladium-catalyzed addition of
the pronucleophile 81 to alkenyl epoxide 82 occurred with
complete transfer of chirality, via a π-allylpalladium spe-
cies, thus creating the proper configuration at C-6. The re-
sulting allylic alcohol 83, which incorporates all stereogenic
centers of fluvirucinin B1, was obtained as a single diaste-
reomer (Scheme 18). Then, simultaneous hydrogenolysis of
Scheme 17  Preparation of the C1–C6 and C7–N fragments in the Amat–Bosch synthesis of fluvirucinin B1
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Scheme 18  Final steps of Trost’s synthesis of fluvirucinin B1
CO2Bn
OH
O
O
O
O
83 HN
OTBS
O
O
O
O
O
HN
OTBS
O
MeO2C
HN
OTBS
O
84
85 86  O-TBS Fluvirucinin B1
Pd2(dba)3
O P O
O
75%
1. TBSOTf
 2. Pd/C, HCO2NH4, 4 kbar
   then PyBroP
    i-Pr2NEt, DMAP
39%
1. LiOH, MeOH, H2O
    then DMSO, 120 ºC
2. TBAF
3. H2, Pd/C
4. TBSOTf
1. LiOH, KCN
    PhOP(O)Cl2
    then PhSeH
2. n-Bu3SnH
     AIBN
46%44%
PyBroP = P
N
N
N
PF6–
Br
5
6
+
5
CO2Bn
OO
OO
O
N3
6
N381 82
1© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2016, 48, 2705–2720
2714
M. Amat et al. Short ReviewSyn thesis
H
er
un
te
rg
el
ad
en
 v
on
: U
ni
ve
rs
id
ad
 d
e 
Ba
rc
el
on
a.
 U
rh
eb
er
re
ch
tlic
h 
ge
sc
hü
tz
t.the benzyl ester and azide functionalities and subsequent
macrolactamization of the resulting amino acid took place
under the reaction conditions depicted in Scheme 18 to
give macrolactam 84.
Once the macrocyclic ring system of fluvirucinin B1 was
assembled, the 1,3-dicarbonyl ester moiety was removed
stepwise by base-catalyzed hydrolysis–decarboxylation of
84 and, after hydrogenation of the olefinic bond, by radical
decarbonylation of the acyl phenylselenide derived from es-
ter 85. The resulting O-silyl derivative 86 had previously
been desilylated to fluvirucinin B1.
The synthesis of the key fragments 81 and 82 is outlined
in Scheme 19. Stereoselective allylation (de >95%) of N-bu-
tyrylimidazolidinone 87, followed by removal of the chiral
auxiliary from imidazolidinone 88, afforded ester 89. After
ozonolysis of the olefinic bond of 89, the Meldrum’s acid
moiety was introduced on the resulting aldehyde 90 by re-
ductive alkylation under Knoevenagel conditions to afford
81.
On the other hand, the synthesis of azide 82 started
with stereoselective alkylation of 87 (≥95% de) leading to
imidazolidinone 91. Reductive removal of the chiral auxilia-
ry followed by oxidation of the resulting alcohol 92 and a
two-carbon homologation–reduction sequence gave allylic
alcohol 93. Asymmetric epoxidation afforded a single dia-
stereomeric epoxide, thus defining the C-9 absolute config-
uration. Subsequent oxidation and a stereoselective Wittig
olefination (7:1 Z/E ratio) of the resulting aldehyde 94 gave
the C6–N fragment 82.
3.2.2 The Vilarrasa–Urpí Approach to Fluvirucinin B1
In 1999, Vilarrasa and Urpí published26 an alternative
synthesis of fluvirucinin B1, also involving a lactamization
reaction to construct the 14-membered ring. The crucial
open-chain precursor 98 was prepared by stereoselective
aldol-like reaction (bond formed C8–C9) between aldehyde
96 and the boron enolate generated from ketone 95 and the
menthone-derived boryl bromide 97 (Scheme 20). Alcohol
98 incorporates all carbon atoms of the target aglycon with
the natural configuration in all stereocenters. After the sub-
sequent conversion of syn alcohol 98 (20:1 syn/anti ratio)
into ω-azido acid 99, the macrolactamization to 100 was
performed via an S-2-pyridyl ester by reduction of the azido
group.
A three-step reduction of the ketone carbonyl and
deprotection of the alcohol function afforded fluvirucinin
B1. The spectroscopic data of the corresponding acetate
matched those reported in the literature.
Both ketone 95 and aldehyde 96 (C1–C8 and C9–N frag-
ments of fluvirucinin B1) were synthesized from a common
intermediate 103, which provided the C-2 and C-10 ethyl-
substituted stereocenters of the target aglycon. Compound
103 was accessible in five steps from the known Evans
N-acyloxazolidinone 101, via alcohol 102,22 as outlined in
Scheme 21.
The preparation of ketone 95 featured a diastereoselec-
tive alkylation of the N-propanoyl derivative of (–)-pseudo-
ephedrine with the iodide derived from 103, a process that
installed the C-6 methyl-substituted stereocenter of flu-
virucinin B1. Removal of the chiral auxiliary with MeLi gave
methyl ketone 95.
Scheme 19  Preparation of the C1–C5 and C6–N fragments in Trost’s synthesis of fluvirucinin B1
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t.In turn, azido aldehyde 96 was obtained from 103 in
three conventional steps: introduction of the azido group,
deprotection, and Swern oxidation.
3.2.3 Suh’s Approach to Fluvirucinin A1
The synthesis of fluvirucinin A1 by Suh in 1999 was the
first synthesis of a member of the fluvirucinin A series.27
Before the final lactamization of amino acid 114, the key
steps were diastereoselective vinyl addition to a 2-piperi-
done derivative, amide–enolate aza-Claisen rearrangement
to generate the 10-membered lactam 109, and stereoselec-
tive condensation of an aldehyde with the boron enolate of
N-propionyloxazolidinone 112.
The synthesis begins with the Evans asymmetric alkyla-
tion of N-acyloxazolidinone 104, to install the initial stereo-
genic center corresponding to C-10 of fluvirucinin A1, and
the conversion of the alkylated product 105 into 2-piperi-
done 106 (Scheme 22). The corresponding N-benzyl deriva-
tive was converted into trans-2,3-disubstituted piperidine
107 via a diastereoselective (95:5 trans/cis ratio) vinylation
at the lactam carbonyl with the assistance of LiAl(OEt)3H.
Exchange of the benzyl group for propionyl gave amide 108,
which underwent stereoselective amide–enolate-induced
aza-Claisen rearrangement (bond formed C6–C7), leading to
the ring-expanded lactam 109, which possesses a new ste-
reogenic center, corresponding to C-6 of fluvirucinin A1.
The reaction occurs via a Z-enolate in a chair–chair-like
transition state bearing an equatorial ethyl substituent.
Scheme 22  Initial steps of Suh’s synthesis of fluvirucinin A1
Scheme 20  Final steps of the Vilarrasa–Urpí synthesis of fluvirucinin B1
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Scheme 21  Preparation of the C1–C8 and C9–N fragments in the Vilarrasa–Urpí synthesis of fluvirucinin B1
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t.Scheme 23  Final steps of Suh’s synthesis of fluvirucinin A1
After unsaturated lactam 109 was hydrogenated and N-
protected, reductive ring-opening of lactam 110, followed
by a two-carbon Wittig olefination and two reduction
steps, afforded saturated aldehyde 111 (Scheme 23). The
two remaining stereocenters (C-2 and C-3) were stereose-
lectively introduced following the Evans protocol by an
aldol-type reaction between aldehyde 111 and N-
propionyloxazolidinone 112. Hydrolytic removal of the
auxiliary and protecting–deprotecting steps converted the
resulting alcohol 113 into amino acid 114. Subsequent lact-
amization and deprotection provided synthetic fluvirucinin
A1, which was identical in all respects to the natural agly-
con.
3.2.4 Fu’s Approach to Fluvirucinin A1
In 2008, Fu reported28 a formal total synthesis of flu-
virucinin A1, using two sequential Ni-catalyzed asymmetric
C(sp3)–C(sp3) Negishi cross-coupling reactions of allylic
chlorides as the key steps.
The synthesis started from ethyl (E)-4-oxo-2-butenoate,
which was converted in two steps into racemic secondary
allylic chloride 116a (Scheme 24).
Nickel(II)-catalyzed cross-coupling of 116a with alkyl-
zinc reagent 115 in the presence of Pybox ligand 117 pro-
vided compound 118 in excellent yield and almost com-
plete regio- (>20:1) and enantioselectivity (96% ee). Com-
pound 118 was converted into bromide 119 and then into
the corresponding alkylzinc derivative, which was subject-
ed to a second nickel(II)-catalyzed asymmetric cross-
coupling reaction with racemic allylic chloride 116b to gen-
erate unsaturated ester 120 in excellent diastereo- (15:1 ra-
tio) and enantioselectivity (>98% ee). A subsequent
reduction–amination sequence provided N-protected ami-
no aldehyde 111, an advanced intermediate in Suh’s synthe-
sis of fluvirucinin A1.
3.3 Construction of the 14-Membered Ring by Aza-
Claisen Ring Expansion
3.3.1 Suh’s Approach to Fluvirucinin A2
In 2010, Suh contributed29 the first total synthesis of
fluvirucinin A2 by iterative lactam ring expansion via an
amide–enolate-induced aza-Claisen rearrangement that
provided the 14-membered lactam skeleton with the re-
quired absolute configuration at all ring stereogenic cen-
ters.
The 10-membered lactam 109, an early intermediate in
Suh’s synthesis of fluvirucinin A1, prepared by an initial
amide–enolate-induced aza-Claisen rearrangement,27 was
converted into N-Boc saturated lactam 121 (Scheme 25).
After partial reduction of the lactam carbonyl and trapping
of the resulting N,O-hemiacetal as a silyl ether, stereoselec-
tive amidoalkylation led to allyl azacycle 122, which was
protected as the Fmoc derivative 123. Oxidative cleavage of
the allyl group to an aldehyde, followed by silylation stereo-
selectively afforded the required (E)-silyl enol ether  124
(E/Z > 10:1).
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Scheme 24  Fu’s formal synthesis of fluvirucinin A1
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t.Scheme 25  Suh’s synthesis of fluvirucinin A2
The corresponding (E)-2-pentenamide 125a underwent
regio- and stereoselective (dr >10:1) vinylogous amide–
enolate-induced aza-Claisen rearrangement, via a highly fa-
vorable transition state, leading to lactam 126 (bond
formed C2–C3), with generation of the C-2 and C-3 stereo-
genic centers. Selective oxidation of the propenyl append-
age of 126, followed by a stereoselective Grignard addition
to the resulting aldehyde, left the (S)-1-hydroxyethyl chain
at C-2. Deprotection of the C-3 hydroxy group and hydroge-
nation of the olefinic double bond completed the synthesis
of fluvirucinin A2, whose diacetate exhibited spectral data
identical to those of the diacetate derived from the natural
aglycon.
The stereoselectivity of the aza-Claisen rearrangement
was dependent on the substitution at the unsaturated
N-acyl moiety. Thus, when starting from N-(3,3-dimethyl-
acryloyl) derivative 125b, the rearrangement was not ste-
reoselective, leading to a 1:1 mixture of macrolactam 127
and its C-2 epimer, probably due to a nonselective forma-
tion of the Z-enolate (Scheme 26).
Compound 127 was converted into epi-fluvirucinin A2
by manipulation of the isopropenyl chain at C-2 and subse-
quent deprotection and hydrogenation steps. The R config-
uration of the 1-hydroxyethyl moiety was attained by ste-
reoselective NaBH4 reduction of a ketone generated by se-
lective oxidative cleavage of the isopropenyl double bond.
The structures of the synthetic fluvirucinin A2 and its
epi-derivative were confirmed by an alternative synthesis
of epi-fluvirucinin A2 employing a Baeyer–Villiger oxidation
to ensure the R configuration of the 1-hydroxyethyl chain.
After acylation of the 10-membered amine intermedi-
ate 122 with the R-configurated mixed anhydride 128 and
conversion of the allyl chain into an (E)-silyl enol ether,
treatment of 129 under aza-Claisen rearrangement condi-
tions afforded the 14-membered lactam 130 (Scheme 27).
The (R)-benzyloxymethyl substituent in the C-2 chain of
130 was converted into (R)-acetyl in 131 and then to (R)-
acetoxy in 132, via a Baeyer–Villiger oxidation with reten-
tion of configuration.
The spectral data of epi-fluvirucinin A2 prepared by this
approach were identical to those of epi-fluvirucinin A2 syn-
thesized by the route depicted in Scheme 26.
Scheme 26  Suh’s synthesis of epi-fluvirucinin A2
3.3.2 The Suh–Jung Stereocontrolled Approach to 
Fluvirucinin A1and Its C-3 Epimer
In the context of a systematic investigation of the aza-
Claisen rearrangement induced ring expansion of azacycles
and its stereochemical outcome, in 2012 Suh and Jung re-
ported30 an alternative synthesis of fluvirucinin A1. Based
on a stereoselective (E)- and (Z)-silyl enol ether formation
and subsequent ring expansion of the resulting 10-mem-
bered 1-acyl-2-alkoxyvinyl azacycles, it provides stereo-
controlled access to both fluvirucinin A1 and its C-3 epimer.
The starting allyl azacycle 133 was stereoselectively
prepared by the procedure outlined in Scheme 25, by ami-
doalkylation of the corresponding lactam.29 Ozonolysis of
133 gave aldehyde 134, which was then converted with al-
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t.most complete stereoselectivity into either the (E)-silyl
enol ether E-135 or the Z-isomer Z-135, depending on the
reaction conditions (Scheme 28).
These silyl enol ethers underwent a stereospecific
amide–enolate-induced aza-Claisen rearrangement (bond
formed C2–C3), via the chair-like transition states depicted
in Scheme 28, providing the respective C-3 isomeric 14-
membered lactams 136 and 3-epi-136, which were then
converted into fluvirucinin A1 and its C-3 epimer.
4 Conclusion
Considerable work remains to be done on the synthesis
of fluvirucins. To date, the only member of this family of
natural products to have been synthesized is fluvirucin B1,
which incorporates 3-amino-3,6-dideoxy-α-L-talopyranose
as the aminosugar moiety. No syntheses of fluvirucins bear-
ing L-mycosamine as the carbohydrate fragment have been
reported.
In contrast, the synthesis of fluvirucinins has attracted
considerable attention and a variety of strategies and pro-
cedures have been employed to assemble the macrocyclic
ring system. Table 1 summarizes the synthetic strategies
used for the construction of the 14-membered ring of flu-
virucinins, showing the bond formed in the macrocycliza-
tion step in each case. Except when the 14-membered ring
is assembled by expansion of a 10-membered ring, the ta-
ble also indicates the bond formed to complete the open-
chain skeleton before the macrocyclization step, as well as
the length of the two fragments used and the ring atoms
they incorporate.
All the reported syntheses are enantioselective and
most of them highly convergent, in many cases accessing
both key intermediates from a single enantiopure building
block. By an appropriate selection of the starting materials,
many of the strategies developed could be applied to the
synthesis of other members of the fluvirucinin family.
Finally, it should be noted that the synthetic activity in
this area has stimulated the development and extensive ap-
plication of new synthetic methodologies such as RCM
macrocyclizations, as well as the use of metal-catalyzed
transformations in crucial synthetic steps.
Scheme 27  Alternative synthesis of epi-fluvirucinin A2
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t.Table 1  Summary of Synthetic Strategies
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